Brookline Capital Markets Estimates Opus Genetics Q2 Earnings

Opus Genetics, Inc. (NASDAQ:IRD) – Brookline Capital Markets issued their Q2 2026 earnings per share (EPS) estimates for shares of Opus Genetics in a report issued on Wednesday, June 10th. Brookline Capital Markets analyst K. Raja expects that the company will post earnings per share of ($0.18) for the quarter. The consensus estimate for Opus Genetics’ current full-year earnings is ($0.97) per share. Brookline Capital Markets also issued estimates for Opus Genetics’ Q3 2026 earnings at ($0.18) EPS.

Several other equities analysts have also recently weighed in on IRD. Craig Hallum set a $9.00 price target on Opus Genetics and gave the company a “buy” rating in a report on Wednesday, March 11th. B. Riley Financial reissued a “buy” rating on shares of Opus Genetics in a report on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Opus Genetics in a report on Tuesday, April 21st. Wedbush increased their price target on Opus Genetics from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Thursday, March 12th. Finally, Leerink Partners started coverage on Opus Genetics in a report on Thursday, May 21st. They set an “outperform” rating and a $10.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, Opus Genetics currently has an average rating of “Moderate Buy” and an average target price of $10.67.

Opus Genetics Price Performance

NASDAQ IRD opened at $3.89 on Thursday. The business’s fifty day moving average price is $4.81 and its 200-day moving average price is $3.63. The stock has a market capitalization of $321.18 million, a price-to-earnings ratio of -2.92 and a beta of 0.56. Opus Genetics has a 1-year low of $0.90 and a 1-year high of $5.81.

Opus Genetics (NASDAQ:IRD) last issued its earnings results on Tuesday, May 12th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.59). Opus Genetics had a negative net margin of 892.36% and a negative return on equity of 338.88%. The business had revenue of $2.16 million for the quarter, compared to analysts’ expectations of $2.93 million.

Insider Buying and Selling

In related news, Director Fighting Blindness Foundation sold 1,700,000 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $4.35, for a total value of $7,395,000.00. Following the transaction, the director directly owned 3,792,171 shares of the company’s stock, valued at approximately $16,495,943.85. This trade represents a 30.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ashwath Jayagopal sold 7,542 shares of the firm’s stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $5.19, for a total value of $39,142.98. Following the completion of the transaction, the insider directly owned 509,233 shares in the company, valued at approximately $2,642,919.27. This represents a 1.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,773,395 shares of company stock worth $7,777,278 in the last quarter. Company insiders own 11.70% of the company’s stock.

Hedge Funds Weigh In On Opus Genetics

A number of institutional investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP bought a new position in Opus Genetics in the 1st quarter worth $611,000. Bank of America Corp DE raised its holdings in Opus Genetics by 2,965.6% in the 1st quarter. Bank of America Corp DE now owns 67,015 shares of the company’s stock worth $305,000 after purchasing an additional 64,829 shares during the period. ADAR1 Capital Management LLC raised its holdings in Opus Genetics by 4,522.5% in the 1st quarter. ADAR1 Capital Management LLC now owns 1,849,004 shares of the company’s stock worth $8,413,000 after purchasing an additional 1,809,004 shares during the period. Regency Capital Management Inc. DE raised its holdings in Opus Genetics by 47.8% in the 1st quarter. Regency Capital Management Inc. DE now owns 68,000 shares of the company’s stock worth $309,000 after purchasing an additional 22,000 shares during the period. Finally, Virtu Financial LLC bought a new position in Opus Genetics in the 4th quarter worth $34,000. 14.97% of the stock is owned by institutional investors.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.